U.S., Dec. 2 -- ClinicalTrials.gov registry received information related to the study (NCT07255638) titled 'A Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in Germany' on Nov. 20.
Brief Summary: This is a non-interventional study assessing the effectiveness of avapritinib (BLU-285) in the management of ISM in real-world settings in Germany. The study also seeks to address the existing data gap in the natural history and management of participants with ISM.
The study is designed to follow each participant up to a maximum of 24 months.
Study Start Date: Dec. 01
Study Type: OBSERVATIONAL
Condition:
Indolent Systemic Mastocytosis
Intervention:
DRUG: Avapritinib
Avapritinib will be administered as an...